Dr. Ralph DeBerardinis, MD, PhD joined the faculty of UT Southwestern Medical Center in 2008 and joined the Children’s Medical Center Research Institute at UTSW (CRI) shortly after its founding in 2012. He is Chief of Pediatric Genetics and Metabolism at UTSW and Director of the Genetic and Metabolic Disease Program at CRI. Dr. DeBerardinis is a Howard Hughes Medical Institute Investigator and has received numerous awards including the William K. Bowes, Jr. Award in Medical Genetics, the National Cancer Institute’s Outstanding Investigator Award, The Academy of Medicine, Engineering & Science of Texas’s Edith and Peter O’Donnell Award in Medicine, and the Paul Marks Prize for Cancer Research from Memorial Sloan Kettering Cancer Center. He has been elected to the National Academy of Medicine and the Association of American Physicians.
Dr. DeBerardinis’ laboratory studies the role of altered metabolic pathways in human diseases, including cancer and pediatric inborn errors of metabolism. The lab has pioneered the use of metabolomics and isotope tracing to characterize disease-associated metabolic states directly in patients, and to use disease-relevant model systems to explore how metabolic perturbations contributes to tissue dysfunction. Work from the DeBerardinis laboratory has produced new insights into disease mechanisms in numerous metabolic diseases, including by defining unexpected fuel preferences in human cancer and uncovering new metabolic vulnerabilities in cancer cells.
Dr. DeBerardinis received a Bachelor of Science in Biology from St. Joseph’s University in Philadelphia before earning M.D. and Ph.D. degrees from the University of Pennsylvania’s School of Medicine. He completed his post-graduate clinical training at The Children’s Hospital of Philadelphia (CHOP) in Pediatrics, Medical Genetics and Clinical Biochemical Genetics. Before coming to UT Southwestern, he performed postdoctoral research at the Penn Cancer Center.
- Name several advances in the diagnosis and treatment of IEMs over the past 25 years
- Discuss the advantages and limitations of clinical genomic analysis in IEM diagnostics
- Explain the utility of integrating advanced metabolomic analysis with genomics in patients suspected to have a monogenic disorder
- Ralph DeBerardinis, MD, PhD
This seminar was delivered as a Pediatric Grand Rounds Lecture at Children’s Hospital of Philadelphia, on April 20, 2022.
The work presented in the presentations, videos, and other content on this site (“Presentations”) includes publicly available medical evidence, a consensus of medical practitioners, and/or opinions of individual practitioners that may differ from consensus opinions. These Presentations are intended only to provide general information and need to be adapted for each specific patient based on the practitioner’s professional judgment, consideration of any unique circumstances, the needs of each patient and their family, the availability of various resources at the health care institution where the patient is located, and other factors. The Presentations are not intended to constitute medical advice or treatment, nor should they be relied upon as such. The Presentations are not intended to create a doctor-patient relationship between/among The Children’s Hospital of Philadelphia, its physicians and the individual patients in question. The information contained in these Presentations are general in nature, and do not and are not intended to refer to specific patients.
CHOP, The Children’s Hospital of Philadelphia Foundation and its or their affiliates, the authors, presenters, practitioners, editors, and others associated with the creation of the Presentations (“CHOP”) are not responsible for errors or omissions in the Presentations; for any outcomes a patient might experience where a clinician reviewed one or more such Presentations in connection with providing care for that patient; and/or for any and all third party content on the site or in the Presentations. CHOP makes no warranty, expressed or implied, with respect to the currency, completeness, applicability or accuracy of the Presentations. Application of the information in or to a particular situation remains the professional responsibility of the practitioner who is directly treating the patient.
To the extent that the Presentations include information regarding drug dosing, in view of ongoing research, changes in government regulations and the constant flow of information relating to drug therapy and drug reactions, the viewer should not rely on the Presentation content, but rather is urged to check the package insert for each drug for indications, dosage, warnings and precautions.
Some drugs and medical devices presented in the Presentations have United States Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the practitioner to ascertain the FDA status of each drug or device planned for use in their clinical practice.
You shall indemnify, defend and hold harmless CHOP, The Children’s Hospital of Philadelphia Foundation, and its/their current and former employees, officers, and agents, trustees, and their respective successors, heirs and assigns (“Indemnitees”) against any claims, liability, damage, loss or expenses (including attorneys’ fees and expenses of litigation) in connection with any claims, suits, actions, demands or judgments arising directly or indirectly out of your reference to or use of the Presentations.
The Presentations are protected by copyright laws and in some cases patent laws, and all rights are reserved under such laws. No part of the Presentations may be reproduced in any form by any means, or utilized in any other way, absent prior written permission from the copyright owner.
By starting this module, you agree to our Content Disclaimer and Terms of Service.
CHOP Employee? Log In Here
**By selecting “Yes”, you consent to receive information from CHOP. Once you have decided to receive such communications, you may later decide to stop receiving these communications. If you want to stop receiving these communications, you may send an email message to firstname.lastname@example.org.